(Q38271353)

1 September 2017

1 reference

title

Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management (English)

1 reference

1 September 2017

Daniel Luedecke

1

1 reference

1 September 2017

Daniel Schöttle

2

1 reference

1 September 2017

Anne Karow

3

1 reference

1 September 2017

Martin Lambert

4

1 reference

1 September 2017

Dieter Naber

5

1 reference

1 September 2017

publication date

1 January 2015

1 reference

1 September 2017

1 reference

1 September 2017

volume

29

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

41-46

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-014-0216-9

1 September 2017

exact match

0 references

cites work

Depot antipsychotic drugs. Place in therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Antipsychotic depot medication and attitudes of community psychiatric nurses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Use of depot antipsychotic medications for medication nonadherence in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Long-acting injectable antipsychotics: focus on olanzapine pamoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Olanzapine pamoate for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

The time-dependant post-mortem redistribution of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Drug safety evaluation of olanzapine pamoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

Guidelines for depot antipsychotic treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0216-9

A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia

21 January 2018

1 reference

12 December 2020

Olanzapine long-acting post-injection syndrome: a case report and brief review

1 reference

12 December 2020

The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

1 reference

12 December 2020

Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia

1 reference

12 December 2020

An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

1 reference

12 December 2020

10.1007/S40263-014-0216-9

Identifiers

DOI

1 reference

1 September 2017

1 reference